A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease

NCT04002830 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Gaucher Disease, Type 3

Interventions

DRUG: Elelyso

Sponsor

Ari Zimran

Collaborators

[object Object]